189 related articles for article (PubMed ID: 33901345)
1. Impact of molecular testing on detecting mimics of oncocytic neoplasms in thyroid fine-needle aspirates diagnosed as follicular neoplasm of Hürthle cell (oncocytic) type.
Landau MS; Nikiforov YE; Ohori NP; Chiosea SI
Cancer Cytopathol; 2021 Oct; 129(10):788-797. PubMed ID: 33901345
[TBL] [Abstract][Full Text] [Related]
2. Molecular alterations in Hürthle cell nodules and preoperative cancer risk.
Doerfler WR; Nikitski AV; Morariu EM; Ohori NP; Chiosea SI; Landau MS; Nikiforova MN; Nikiforov YE; Yip L; Manroa P
Endocr Relat Cancer; 2021 Apr; 28(5):301-309. PubMed ID: 33792557
[TBL] [Abstract][Full Text] [Related]
3. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay.
Nikiforov YE; Carty SE; Chiosea SI; Coyne C; Duvvuri U; Ferris RL; Gooding WE; Hodak SP; LeBeau SO; Ohori NP; Seethala RR; Tublin ME; Yip L; Nikiforova MN
Cancer; 2014 Dec; 120(23):3627-34. PubMed ID: 25209362
[TBL] [Abstract][Full Text] [Related]
4. Hürthle cell lesions on thyroid fine needle aspiration cytology: Molecular and histologic correlation.
Schatz-Siemers N; Brandler TC; Oweity T; Sun W; Hernandez A; Levine P
Diagn Cytopathol; 2019 Oct; 47(10):977-985. PubMed ID: 31293091
[TBL] [Abstract][Full Text] [Related]
5. ThyroSeq v3 for Bethesda III and IV: An institutional experience.
Desai D; Lepe M; Baloch ZW; Mandel SJ
Cancer Cytopathol; 2021 Feb; 129(2):164-170. PubMed ID: 33030808
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors.
Jung CK; Kim Y; Jeon S; Jo K; Lee S; Bae JS
Hum Pathol; 2018 Nov; 81():9-17. PubMed ID: 29723601
[TBL] [Abstract][Full Text] [Related]
7. Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules.
Brauner E; Holmes BJ; Krane JF; Nishino M; Zurakowski D; Hennessey JV; Faquin WC; Parangi S
Thyroid; 2015 Jul; 25(7):789-96. PubMed ID: 25962906
[TBL] [Abstract][Full Text] [Related]
8. Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules.
Nikiforova MN; Mercurio S; Wald AI; Barbi de Moura M; Callenberg K; Santana-Santos L; Gooding WE; Yip L; Ferris RL; Nikiforov YE
Cancer; 2018 Apr; 124(8):1682-1690. PubMed ID: 29345728
[TBL] [Abstract][Full Text] [Related]
9. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
Witt RL
Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic performance of molecular testing in indeterminate (Bethesda III and IV) thyroid nodules with Hürthle cell cytology.
Raghunathan R; Longstaff XR; Hughes EG; Li SJ; Sant VR; Tseng CH; Rao J; Wu JX; Yeh MW; Livhits MJ
Surgery; 2024 Jan; 175(1):221-227. PubMed ID: 37926582
[TBL] [Abstract][Full Text] [Related]
11. "Copy number alteration" as the sole molecular finding of a Thyroseq test is more commonly seen in Hurthle cell neoplasms.
Kim TH; Rodriguez EF; Lim D; Moatamed NA
Diagn Cytopathol; 2023 Nov; 51(11):705-711. PubMed ID: 37533334
[TBL] [Abstract][Full Text] [Related]
12. PREDICTIVE VALUE OF SOMATIC MUTATIONS FOR THE DEVELOPMENT OF MALIGNANCY IN THYROID NODULES BY CYTOPATHOLOGY.
Halászlaki C; Tóbiás B; Balla B; Kósa JP; Horányi J; Bölöny E; Nagy Z; Speer G; Járay B; Székely E; Istók R; Székely T; Putz Z; Dank M; Lakatos P; Takács I
Endocr Pract; 2016 Sep; 22(9):1081-7. PubMed ID: 27214302
[TBL] [Abstract][Full Text] [Related]
13. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
Pu RT; Yang J; Wasserman PG; Bhuiya T; Griffith KA; Michael CW
Diagn Cytopathol; 2006 May; 34(5):330-4. PubMed ID: 16604553
[TBL] [Abstract][Full Text] [Related]
14. Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules.
Beaudenon-Huibregtse S; Alexander EK; Guttler RB; Hershman JM; Babu V; Blevins TC; Moore P; Andruss B; Labourier E
Thyroid; 2014 Oct; 24(10):1479-87. PubMed ID: 24811481
[TBL] [Abstract][Full Text] [Related]
15. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer.
Nikiforova MN; Wald AI; Roy S; Durso MB; Nikiforov YE
J Clin Endocrinol Metab; 2013 Nov; 98(11):E1852-60. PubMed ID: 23979959
[TBL] [Abstract][Full Text] [Related]
16. Adenomatoid nodules are the main cause for discrepant histology in 234 thyroid fine-needle aspirates reported as follicular neoplasm.
Schreiner AM; Yang GC
Diagn Cytopathol; 2012 May; 40(5):375-9. PubMed ID: 22508673
[TBL] [Abstract][Full Text] [Related]
17. How limited molecular testing can also offer diagnostic and prognostic evaluation of thyroid nodules processed with liquid-based cytology: Role of TERT promoter and BRAF V600E mutation analysis.
Dell'Aquila M; Fiorentino V; Martini M; Capodimonti S; Cenci T; Lombardi CP; Raffaelli M; Pontecorvi A; Fadda G; Pantanowitz L; Larocca LM; Rossi ED
Cancer Cytopathol; 2021 Oct; 129(10):819-829. PubMed ID: 34076961
[TBL] [Abstract][Full Text] [Related]
18. Molecular Profiling of 50 734 Bethesda III-VI Thyroid Nodules by ThyroSeq v3: Implications for Personalized Management.
Chiosea S; Hodak SP; Yip L; Abraham D; Baldwin C; Baloch Z; Gulec SA; Hannoush ZC; Haugen BR; Joseph L; Kargi AY; Khanafshar E; Livhits MJ; McIver B; Patel K; Patel SG; Randolph GW; Shaha AR; Sharma J; Stathatos N; van Zante A; Carty SE; Nikiforov YE; Nikiforova MN
J Clin Endocrinol Metab; 2023 Oct; 108(11):2999-3008. PubMed ID: 37071871
[TBL] [Abstract][Full Text] [Related]
19. Malignancy risk for solitary and multiple nodules in Hürthle cell-predominant thyroid fine-needle aspirations: A multi-institutional study.
Wong KS; Jo VY; Lowe AC; Faquin WC; Renshaw AA; Shah AA; Roh MH; Stelow EB; Krane JF
Cancer Cytopathol; 2020 Jan; 128(1):68-75. PubMed ID: 31751003
[TBL] [Abstract][Full Text] [Related]
20. Does the fine-needle aspiration diagnosis of "Hürthle-cell neoplasm/follicular neoplasm with oncocytic features" denote increased risk of malignancy?
Giorgadze T; Rossi ED; Fadda G; Gupta PK; Livolsi VA; Baloch Z
Diagn Cytopathol; 2004 Nov; 31(5):307-12. PubMed ID: 15468114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
